Oragenics Inc - Asset Resilience Ratio
Oragenics Inc (OGEN) has an Asset Resilience Ratio of 39.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Oragenics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Oragenics Inc's Asset Resilience Ratio has changed over time. See OGEN total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Oragenics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Oragenics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.00 Million | 39.73% |
| Total Liquid Assets | $4.00 Million | 39.73% |
Asset Resilience Insights
- Very High Liquidity: Oragenics Inc maintains exceptional liquid asset reserves at 39.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oragenics Inc Industry Peers by Asset Resilience Ratio
Compare Oragenics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK |
Biotechnology | 52.08% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT |
Biotechnology | 41.14% |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658 |
Biotechnology | 10.25% |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX |
Biotechnology | 14.01% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for Oragenics Inc (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Oragenics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.73% | $4.00 Million | $10.07 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $1.47 Million | -- |
| 2022-12-31 | 0.12% | $17.94K | $14.76 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $7.21 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $4.31 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $5.78 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $11.13 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $16.83 Million | -- |
| 2012-12-31 | 0.59% | $62.00K | $10.49 Million | -20.33pp |
| 2011-12-31 | 20.92% | $265.00K | $1.27 Million | -6.64pp |
| 2010-12-31 | 27.55% | $476.00K | $1.73 Million | -48.94pp |
| 2009-12-31 | 76.49% | $2.45 Million | $3.20 Million | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more